Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Idiopathic Parkinson Disease
Interventions
XADAGO (safinamide)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Homewood, Alabama • Bakersfield, California • Laguna Hills, California + 27 more
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 86 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Conditions
Parkinson Disease
Interventions
CVN424 75 mg, CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
Conditions
Parkinson Disease, Parkinson Disease, Idiopathic
Interventions
Community Walking Program
Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
30 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Idiopathic Parkinson's Disease
Interventions
Istradefylline 20 mg or 40 mg
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
30 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 20 more
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinimide 50-100 mg/day, Matching Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, IPX054 300 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Sunnyvale, California • Lawrence, Kansas
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson's Disease
Interventions
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
21
States / cities
Phoenix, Arizona • Aliso Viejo, California • Irvine, California + 17 more
Completed Phase 4 Interventional Results available

Lundbeck TOMs Orthostatic Hypotension

NCT04510922
Conditions
Orthostatic Hypotension, Idiopathic Parkinson Disease
Interventions
Droxidopa 100 MG [Northera]
Drug
Lead sponsor
Alberto Espay, MD, MSc
Other
Eligibility
30 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Completed Not applicable Interventional Results available

Voice Treatment for Parkinson's Disease

NCT03700684
Conditions
Idiopathic Parkinson Disease
Interventions
Lee Silverman Voice Treatment, SpeechVive, Control
Behavioral · Device
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
West Lafayette, Indiana • Amherst, Massachusetts
Conditions
Idiopathic Parkinson Disease
Interventions
CTC-413
Combination Product
Lead sponsor
Chase Therapeutics Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Farmington Hills, Michigan
Conditions
Idiopathic Parkinson Disease
Interventions
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors, Saline
Biological · Other
Lead sponsor
The Neurology Center
Other
Eligibility
45 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Measuring Parkinson's Disease With Tear Fluid

NCT03037463
Conditions
Idiopathic Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
35 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Parkinson's Disease
Interventions
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Idiopathic Parkinson's Disease (PD)
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Idiopathic Parkinson's Disease
Interventions
CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sham Surgery
Biological · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 6 more
Conditions
Parkinson Disease
Interventions
Group A - Early Imaging, Group B - Delayed Imaging
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Observational cohort
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
Conditions
Parkinson's Disease
Interventions
ExAblate Transcranial System
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Conditions
Parkinson's Disease
Interventions
ExAblate Transcranial MRgFUS, Sham ExAblate Transcranial MRgFUS
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Charlottesville, Virginia • Seattle, Washington